Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

开始日期2025-09-18

申办/合作机构-

RBR-6tnqpjm

/ RecruitingN/A

Prevention of Osteoradionecrosis of the jaw with the drug combination of Pentoxifylline and Tocopherol: randomized clinical trial - PENTO Pentoxifylline and tocopherol

开始日期2024-06-15

申办/合作机构

Sociedade Pernambucana de Combate ao Câncer

[+1]

NCT05795647

/ Recruiting临床2期IIT

The PENTO Protocol in Medication-related Osteonecrosis of the Jaw

Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or targeted therapies. It leads to a significant decrease in quality of life with pain, eating and chewing disorders, and malnutrition. Current treatments are only partially effective. PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary osteoradionecrosis. The objective of this study is to evaluate the proportion of bone recovery in patients receiving PENTO in MRONJ at 12 months.

开始日期2024-02-29

申办/合作机构

Centre Hospitalier Universitaire de Limoges

100 项与生育酚醋酸酯相关的临床结果

登录后查看更多信息

100 项与生育酚醋酸酯相关的转化医学

登录后查看更多信息

100 项与生育酚醋酸酯相关的专利（医药）

登录后查看更多信息

3,121

项与生育酚醋酸酯相关的文献（医药）

2025-10-01·FOOD CHEMISTRY

Mechanism of the secondary metabolites and key enzymes of Monascus spp. to promote tocopherol enrichment

Article

作者: Qin, Likang ; Yang, Xin ; Sun, Yichun ; Qi, Zhengfang ; Wen, Anyan ; Zhang, Nana ; Zeng, Haiying ; Li, Xuanchen

Monascus-fermented coix seed exhibits enhanced tocopherol accumulation compared to other strains, yet mechanisms remain unclear. Whether Monascus metabolites/enzymes drive this enrichment is worth exploring. Comparative genomics and transcriptomics were employed to analyze secondary metabolite profiles and tocopherol enrichment capabilities across Monascus strains. The results revealed that γ-aminobutyric acid (GABA) derived from amino acid metabolism is channeled into both the Shikimate pathway to generate homogentisic acid (a tocopherol precursor) and the Mevalonate pathway to produce ergosterol and geranylgeranyl diphosphate (another precursor). Furthermore, the total tocopherol content of M1 and M1 + 3 reached 168 and 148 μg/g DW, positively correlating with ergosterol content (p < 0.05). Transcriptomic data further demonstrated strain-specific differences in tocopherol enrichment, linked to upregulated expression of key genes (HPPD, ERG4, MVD, FDPS, GGPS1) governing precursor biosynthesis. Crucially, we validated that ergosterol acts as a stimulator of tocopherol synthesis, directly supporting our hypothesis on pathway crosstalk. This study elucidates microbial-driven tocopherol enrichment mechanisms via precursor allocation and transcriptional regulation, providing insights into bioactive compound synthesis in complex metabolic networks.

2025-08-01·COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS

Buffalo whey proteins - Vitamin E macromolecular bioinspirated complexes. Formation and performance at air/water interface

作者: Bustos, Leandro Fabian ; Perez, Oscar Edgardo ; Ruiz-Henestrosa, Victor Manuel Pizones ; Vasile, Franco Emanuel ; Carrera-Sanchez, Cecilio

Buffalo whey protein concentrate (BWPC) is a value-added product that can be obtained from using of buffalo whey.This ingredient has potentiality to protect and delivering sensitive bioactive compounds which in turn can improve its functionality.Therefore, this work aims with the verification of BWPC-Vitamin E complexes/aggregates formation within the aqueous medium subphase followed by the evaluation of their functionality at the A/W interface.To this ends, fluorescence spectroscopy, particle size distribution, ζ-potential, surface hydrophobicity jointly with transmission electron microscopy were performed at bulk phase.Besides, measurements of surface tension at the equilibrium, evolution of surface tension and dilatational rheol. with time, and foaming properties were performed at surface level.The study culminates with the foaming properties defined by these systems.BWPC and vitamin E constituted macromol. complexes, inducing rounded and also elongated shaped aggregates formation in the nanoscale with high colloidal stability.BWPC-Vitamin E complexes were more surface-active at the A/W interface but their films resulted to be less elastic than the single BWPC ones.Finally, foaming capacity and foams stability of aggregates systems were superior than those generated by the single protein.The results obtained here evidence the potentiality of BWPC to be used as a carrier for vitamin E favoring, in turn, the functionality of this protein source at the A/W interface.

2025-07-01·ACS Omega

Harnessing Machine Learning to Revolutionize Electrochemical Detection of Vitamin E Acetate in E-Liquids

Article

作者: Güner, Timuçin ; Kaya, Tarık ; Yaşar, Esra ; Dokuzparmak, Emre ; Özçelik, Hilal ; Akgöl, Sinan ; Sezer, Emine

This study presents the development of a novel molecularly imprinted electrochemical sensor for the sensitive and selective detection of vitamin E acetate (VEA) in e-cigarette liquids, a critical step in addressing the rising public health concern of e-cigarette, or vaping, product use-associated lung injury. VEA-imprinted polymeric nanoparticles, intended to serve as the recognition element on the sensor surface, were synthesized using surfactant-free emulsion polymerization. The synthesized polymer was characterized using Fourier Transformed Infrared Spectroscopy, scanning electron microscope, and zeta potential analyses. The sensor, fabricated using VEA-imprinted poly-(HMA-co-PA)/Nafion on screen-printed carbon electrodes, demonstrated a limit of quantification (LoQ) of 112.3 μg/mL (3.3× S/N) with a wide linear range extending to 3.0 mg/mL (10× S/N). While the sensor exhibited limitations in detecting VEA at concentrations below the LoQ, the integration of machine learning algorithms effectively mitigated these challenges. Machine learning models successfully classified the presence of VEA, even at subdetection limit concentrations, significantly enhancing the sensor's analytical capabilities. Rigorous testing on real-world e-cigarette liquid samples yielded high recovery rates (96.83% ± 2.79-102.56% ± 3.84), validating the sensor's accuracy and selectivity in complex matrices. This research not only establishes a promising platform for the rapid and sensitive detection of VEA in e-cigarette liquids but also underscores the transformative potential of integrating artificial intelligence with sensor technologies for addressing critical public health challenges.

项与生育酚醋酸酯相关的新闻（医药）

2025-08-12

·EINPresswire

Kalani AB dba Kalani Sunwear - 710998 - 08/06/2025

Delivery Method: Via Email Product: Drugs Recipient: Recipient Name Anna Xavier Kalani AB dba Kalani Sunwear Brahegatan 28 114 37 Stockholm Sweden info@kalani.se Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER August 6, 2025 RE: 710998 Dear Ms. Xavier: This letter is to advise you that on May 7th, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website, https://kalanisunwear.com/, where your “Kalani sunwear SUN MOUSSE SPF 50” drug product is available for purchase in the United States without a prescription. We also reviewed your social media pages on Instagram at “kalanisunwear,” which directs consumers to your website to purchase your product, and your Facebook at “Kalani.” Your “Kalani sunwear SUN MOUSSE SPF 50” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Examples from the “Kalani sunwear SUN MOUSSE SPF 50” product labeling, including your website and social media pages listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following: “SUNSCREEN MOUSSE SPF 50… Sunscreen SPF 50… WARNINGS:… Reducing the quantity of sunscreen product applied will lower the level of protection significantly” [from the label of your product on your product website] “Introducing our Kalani sunwear Sun Mousse SPF 50: your ultimate defence against the sun’s rays!” [from your product website] “ High Sun Protection (SPF 50) . Experience top-tier protection against harmful UV rays, ensuring your skin stays safeguarded in the sunniest conditions… Wide Spectrum Protection . Guard your skin against UVA and UVB rays with our broad-spectrum formula, leaving no room for compromise.” [from your product website] “Say goodbye to sunburns and hello to radiant, protected skin! Discover the ultimate sun mousse that feels as light as a cloud while giving you SPF 50 protection…” [from your Instagram social media page] Based on the above labeling, your “Kalani sunwear SUN MOUSSE SPF 50” is intended for use as an over-the-counter (OTC) sunscreen drug product. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for your drug product. Section 505G of the FD&C Act, 21 U.S.C. 355h, governs the marketing of nonprescription drugs that are marketed without an approved application under section 505 of the FD&C Act, 21 U.S.C. 355, such as your product. Under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), a nonprescription drug is misbranded if the drug is subject to section 505G of the FD&C Act, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355. Section 505G of the FD&C Act, 21 U.S.C. 355h, provides that certain nonprescription drugs are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if they, among other things, conform to the conditions in the applicable OTC monograph. In the case of OTC sunscreen drug products, the applicable OTC monograph is set forth in the final administrative order, OTC000006: Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020), which was deemed a final order by 505G(b)(8) and 505G(k)(2)(B). 1 However, under section 505G(m)(2), “notwithstanding subsection [505G](a),” sunscreens in dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder may only be lawfully marketed, without an application approved under section 505 of the FD&C Act, pursuant to an order issued under section 505G of the FD&C Act. 2 To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing of sunscreen in a foam (aka mousse) dosage form, 3 . As previously stated, there is no FDA-approved application in effect for your drug product. Thus, even if your product was in conformity with the conditions set forth in M020 and all other applicable requirements to be deemed GRASE and not a new drug under section 505G(a)(1), it does not comply with the requirements under section 505G. Accordingly, your “Kalani sunwear SUN MOUSSE SPF 50” is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). The introduction or delivery for introduction of misbranded drugs into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Additionally, the formulation for your “Kalani sunwear SUN MOUSSE SPF 50” does not comply with the conditions specified under M020. Specifically, to conform to the conditions of the monograph, your product must contain at least one of the active ingredients listed in § M020.10. Certain combinations of active ingredients are also permitted, as set out in § M020.20(a). We note that your “Kalani sunwear SUN MOUSSE SPF 50” label does not identify any of the ingredients as active ingredients; however, of your product’s labeled ingredients: “Aqua, Diethylamino Hydroxybenzoyl Hexyl Benzoate, Dibutyl Adipate, Phenethyl benzoate, C12-15 Alkyl Benzoate, Butane, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Trimethylpentanediol/Adipic Acid/Glycerin Crosspolymer, Propane, Ethylhexyl Triazone, Palmitic Acid, lsobutane, Stearic Acid, Silica, Phenoxyethyl Caprylate, Cetearyl Alcohol, Tocopheryl Acetate, Sorbitan Laurate, Polyglyceryl-4 Laurate/ Succinate, Triethanolamine, Tetrasodium Glutamate Diacetate” none are permitted active ingredients under M020 when used in combination or as sole ingredients. Therefore, as formulated and labeled, “Kalani sunwear SUN MOUSSE SPF 50” does not comply with the applicable conditions specified in M020 and has not otherwise been found GRASE. Accordingly, “Kalani sunwear SUN MOUSSE SPF 50” is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p) and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no application in effect for this product, this product is an unapproved new drug. Introduction or delivery for introduction of such products into interstate commerce violates section 301(d) of the FD&C Act, 21 U.S.C. 331(d). Conclusion The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name and the unique identifier “710998” in the subject line of your email. Sincerely, /S/ Tina Smith, M.S. Captain, U.S. Public Health Service Director Office of Unapproved Drugs and Labeling Compliance Office of Compliance Center for Drug Evaluation and Research U.S. Food and Drug Administration _____________________________ 1 See sections 505G(a)(1) and (2) of the FD&C Act and see Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, https://dps.fda.gov/omuf. As required by section 505G(a)(2), M020 encompasses the requirements specified in part 352 of title 21, Code of Federal Regulations, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in section 201.327 of title 21, Code of Federal Regulations. 2 Section 505G(m)(2) provides that “[n]otwithstanding subsection [505G](a),” a drug that, “prior to the date of the enactment of this section [March 27, 2020], the Secretary determined in a proposed or final rule to be ineligible for review under the OTC drug review” (emphasis added) may not be legally marketed without an approved NDA or ANDA except as “pursuant to an order issued under this section”. In a 2019 proposed rule, FDA determined that sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder were ineligible for review under the OTC Drug Review under the then-operative requirements because we did not receive data showing that they were marketed prior to 1972. 84 FR 6204 at 6229-6230 (Feb. 26, 2019); see also 84 FR 6204 at 6206 and 6272. Therefore, under section 505G(m)(2) of the FD&C Act, a sunscreen in any dosage form other than the ten dosage forms listed above may only be marketed with an approved application, unless FDA determines otherwise in an order issued under section 505G of the FD&C Act. To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing of sunscreen in a foam (aka) mousse dosage form. 3 The principal display panel of your product label, as well as other labeling, uses the term “mousse” to describe your product. “Foam” is the dosage form term in United States Pharmacopeia (USP) general chapter <1151>, Pharmaceutical Dosage Forms, that best corresponds to your product; “mousse” is not used in that reference. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-05-21

·EINPresswire

AOB Pharma reveals new metabolomic insights of B244, suggesting investigation of potential new avenues for treatment

AOB Pharma reveals new insights via metabolomic analysis of B244, supporting clinical readouts & suggesting investigation of potential new avenues for treatment CAMBRIDGE, MA, UNITED STATES, May 21, 2025 / EINPresswire.com / -- AOB Pharma reveals new mechanistic insights via metabolomic analysis of B244, supporting clinical readouts and suggesting investigation of potential new avenues for treatment • B244 produces numerous skin-beneficial metabolites including ceramides, retinoids, tocopherol, and niacinamide • The presence of these anti-inflammatory and skin-beneficial compounds suggest additional ways that B244 can improve atopic dermatitis and other inflammatory skin diseases • Mining of additional metabolomic data may additionally suggest new indications for which B244 can be used • Select data will be presented by Dan Brownell, AOBiome’s Senior Director of R&D, at the Dermatology Drug Development Summit Europe, taking place in Berlin May 27-28, 2025 CAMBRIDGE, MA, May 21, 2025. AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions, shares new data showing that B244, their lead asset, secretes a suite of anti-inflammatory and beneficial skin metabolites. Metabolomic analysis of B244 has revealed the production of various ceramides, retinoids, tocopherol, niacinamide, and many other compounds critical for skin health. These compounds, in addition to the previously understood mechanisms of action, further highlight the multifactorial benefits of B244 for the potential treatment of additional inflammatory diseases. Ceramides are essential lipids that help maintain the skin's natural barrier, which is often compromised in people with atopic dermatitis. By replenishing ceramide levels, the skin can maintain moisture, reduce dryness, and protect the skin from irritants and allergens. This strengthens the skin’s defense, soothes inflammation, and reduces flare-ups, making ceramides a tool in the maintenance of skin health. Other metabolites produced by B244 have similar potential benefits that justify investigation for use in treatment, including reducing inflammation, antioxidant effects, improvement in skin appearance associated with various skin disorders. “B244 is clearly more than simply a probiotic: these active metabolites have the potential to support the skin in multiple ways simultaneously, unlike any product currently in the marketplace. There is tremendous potential here to revolutionize our understanding of the role of bacteria in skin health and resilience” says Peter Lio, MD, Founding Partner, Medical Dermatology Associates of Chicago. AOBiome is currently preparing to initiate a global Phase 3 study to evaluate B244 for the treatment of mild-to-moderate Atopic Dermatitis and associated moderate-to-severe itch, following the successful completion of a 547 patient Phase 2b study. In addition to the previously understood mechanisms of B244, these new metabolomic insights further suggest the range of improvements of AD symptoms seen clinically. “From an evolutionary standpoint, this further highlights the potential need for ammonia oxidizing bacteria for not only maintaining healthy skin, but treating inflammatory conditions that we did not evolve to have” says President and CEO Todd Krueger. About B244 AOBiome’s B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be safe and well-tolerated in clinical studies to date. Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. See full article at: https://www-nature-com.libproxy1.nus.edu.sg/articles/s41598-021-93299-1 . About AOB Pharma, Inc. AOB Pharma, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical therapeutics for inflammatory conditions. AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. Learn more at AOBiome.com . For Media Inquiries: Jim Hoffman AOBiome Therapeutics +1 617-639-9980 Press@aobiome.com Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床2期微生物疗法

2024-08-23

·ETPharma

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

上市批准

100 项与生育酚醋酸酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01735	生育酚醋酸酯	A11HA03	DB14003

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
动脉粥样硬化	日本	Sannova KK	1963-01-01
糖尿病性视网膜病变	日本	Sannova KK	1963-01-01
冻伤	日本	Sannova KK	1963-01-01
间歇性跛行	日本	Sannova KK	1963-01-01
血栓形成	日本	Sannova KK	1963-01-01
静脉血栓栓塞	日本	Sannova KK	1963-01-01
维生素E缺乏症	日本	Alfresa Pharma Corp.	1961-12-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02251041 (CAPITL, CTgov)	临床2期	再灌注损伤	143	C1-Inhibitor+Epoprostenol+Infliximab+Melatonin+Alfa-tocopherol+Human recombinant erythropoietin+Glutathione	範願獵醖顧網願糧網衊 = 窪襯願觸餘淵壓鹹齋鑰選簾襯膚衊衊艱獵鬱範 (憲窪夢選襯鹹鏇蓋鬱簾, 製糧網膚淵獵壓餘憲構 ~ 鹹顧構獵襯遞餘顧築簾) 更多	-	2024-08-23
NCT02911688 (Gammoz, CTgov)	临床2期	过敏性哮喘	18	gamma tocopherol (Gamma Tocopherol)	選餘製築艱餘鑰網鏇築(窪製選獵積遞艱鏇繭遞) = 繭鹹鑰構簾觸製願憲築繭積鹹夢衊糧鏇窪衊願 (鹹製襯獵壓顧憲醖夢觸, 65.9) 更多	-	2020-01-18
NCT02911688 (Gammoz, CTgov)	临床2期	过敏性哮喘	18	Placebo (Placebo)	選餘製築艱餘鑰網鏇築(窪製選獵積遞艱鏇繭遞) = 齋夢蓋窪壓夢淵夢憲選繭積鹹夢衊糧鏇窪衊願 (鹹製襯獵壓顧憲醖夢觸, 687) 更多	-	2020-01-18
NCT02104505 (Vitalps, CTgov)	临床1/2期	轻度哮喘	23	Placebo	範網鬱蓋膚繭簾夢觸遞(淵膚餘觸繭觸範觸積鏇) = 願艱憲艱衊憲壓觸網鑰衊膚衊築齋網遞範網壓 (鏇築壓糧鏇夢艱鹹襯網, 16.5) 更多	-	2017-11-06